Zydus Lifesciences shares rose 7% following USFDA's final approval to market Dasatinib tablets across multiple strengths. The ...

Zydus Lifesciences Ltd on Wednesday (March 5) said it has received final approval from the United States Food and Drug ...

A new pilot study known as STAMINA (Senolytics To Alleviate Mobility Issues and Neurological Impairments in Aging), that focused on the effects of senolytic medications, Dasatinib and Quercetin (DQ), ...

The uptick in Zydus Life share price came after the company announced that it has received final approval from the USFDA to ...

Dasatinib is prescribed for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in adults.

The rise in Biocon share price came after the company announced that its wholly-owned subsidiary, Biocon Pharma, has received ...

A pilot study indicates that senolytic medications, Dasatinib and Quercetin, may improve cognitive function in older adults at risk for Alzheimer's disease by targeting senescent cells.

Dasatinib is the generic version of Sprycel® tablets, a medication widely used for treating Ph+, chronic myeloid leukemia ...

Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) ...

A new pilot study known as STAMINA (Senolytics To Alleviate Mobility Issues and Neurological Impairments in Aging), that focused on the effects of senolytic medications, Dasatinib and Quercetin ...

With annual US sales of $1.81 billion, as per IQVIA MAT data (January 2025), this approval marks a significant milestone for Zydus. The company will manufacture Dasatinib at its Ahmedabad SEZ facility ...